Study Experimentally Validates Compugen's Computationally Predicted Drug Target for Multiple Myeloma | GenomeWeb

This story originally ran on May 11.

Israeli drug and diagnostics discovery firm Compugen said today that it has completed initial experimental validation for membrane protein CGEN-928 as a drug target for the treatment of multiple myeloma.

The company said that the protein's expression profile indicates that it might also be useful as a diagnostic and prognostic marker for multiple myeloma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.